



NDA 021447

**NOTIFICATION OF
NON-COMPLIANCE WITH PREA**

Acorda Therapeutics, Inc.
Attention: William Pfister, Ph.D.
Senior Director, Regulatory Affairs
420 Saw Mill River Road
Ardsley, New York 10502

Dear Dr. Pfister:

Please refer to your New Drug Application (NDA) submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (the Act) for Zanaflex (tizanidine) capsules, which was approved on August 29, 2002.

The Agency has determined that you have failed to meet the postmarketing requirement (PMR) of the Pediatric Research Equity Act (PREA) for this application because you have not yet submitted your pediatric assessment for PMR 1739-1, which was deferred until December 31, 2005.

Under the provisions of title V, section 505, of the Food and Drug Administration Safety and Innovation Act of 2012 (FDASIA), you must respond in writing within 45 calendar days of the date of this letter. Your response should include the reason(s) for the delayed pediatric assessment and a date by which you expect to submit the assessment. You may also include a request for a deferral extension, if applicable, which should be identified as a “**DEFERRAL EXTENSION REQUESTED**” in your response. We note that you requested a deferral extension on October 15, 2014; however, we have determined that your request does not qualify for an extension.

In accordance with FDASIA, FDA will post this letter and your response on the website located at <http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/ucm343203.htm> with redactions for any trade secrets and confidential commercial information 60 calendar days from the date of this letter.

Please identify your response to this letter as a “**RESPONSE TO PREA NON-COMPLIANCE LETTER.**” To facilitate our review, submit this information to your NDA with a cross-reference letter to the IND to which your protocol has been submitted. In addition, send a copy of the cover letter to CDER’s Pediatric and Maternal Health Staff.

If you have any questions, contact Taura Holmes, Pharm.D., Regulatory Project Manager, via email or telephone at Taura.Holmes@fda.hhs.gov or (301) 796-1932.

Sincerely,

{See appended electronic signature page}

Billy Dunn, M.D.
Director
Division of Neurology Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

WILLIAM H Dunn
03/19/2015